RAD21: A Key Transcriptional Regulator in the Development of Residual Liver Cancer

References

• Rizzo A, Ricci AD, Brandi G. Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: an Update. J Pers Med. 2022;12(11). doi:10.3390/jpm12111788
   Web of Science ®Google Scholar
• Kamal A, Elmoety AAA, Rostom YAM, Shater MS, Lashen SA. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol. 2019;10(3):562–571. doi:10.21037/jgo.2019.01.34
   PubMed Web of Science ®Google Scholar
• Munoz NM, Dupuis C, Williams M, et al. Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma. Commun Biol. 2020;3(1):783. doi:10.1038/s42003-020-01522-y
   PubMed Web of Science ®Google Scholar
• Chen J, Peng K, Hu D, et al. Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. Cancers (Basel). 2018;10(10). doi:10.3390/cancers10100378
   Web of Science ®Google Scholar
• Radosevic A, Quesada R, Serlavos C, et al. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled Phase 2 trial. Sci Rep. 2022;12(1):316. doi:10.1038/s41598-021-03802-x
   PubMedGoogle Scholar
• Maeda M, Saeki I, Sakaida I, et al. Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: a Multicenter Study Involving 9411 Japanese Patients. Liver Cancer. 2020;9(1):50–62. doi:10.1159/000502744
   PubMed Web of Science ®Google Scholar
• Wang J, Liang P, Yu J, et al. Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases. Oncol Lett. 2014;8(1):323–326. doi:10.3892/ol.2014.2106
   PubMed Web of Science ®Google Scholar
• Sutter O, Fihri A, Ourabia-Belkacem R, Sellier N, Diallo A, Seror O. Real-Time 3D Virtual Target Fluoroscopic Display for Challenging Hepatocellular Carcinoma Ablations Using Cone Beam CT. Technol Cancer Res Treat. 2018;17:1533033818789634. doi:10.1177/1533033818789634
   Web of Science ®Google Scholar
• Wang Z, Liu M, Zhang DZ, et al. Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC. Hepatology. 2022;76(1):66–77. doi:10.1002/hep.32323
   PubMed Web of Science ®Google Scholar
• Cui R, Wang XH, Ma C, et al. Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: a Propensity Score Matching Analysis. Cancer Manag Res. 2019;11:10695–10704. doi:10.2147/CMAR.S213581
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–2589. doi:10.2217/fon-2020-0669
   PubMed Web of Science ®Google Scholar
• Qin Z, Xiang C, Zhong F, et al. Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. J Exp Clin Cancer Res. 2019;38(1):154. doi:10.1186/s13046-019-1131-1
   PubMedGoogle Scholar
• Li N, Zheng D, Xue J, et al. Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest. Exp Ther Med. 2015;9(5):1709–1718. doi:10.3892/etm.2015.2351
   PubMed Web of Science ®Google Scholar
• Ren Y, Cao Y, Ma H, et al. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study. BMC Cancer. 2019;19(1):983. doi:10.1186/s12885-019-6237-5
   PubMed Web of Science ®Google Scholar
• Kong J, Yao C, Ding X, et al. ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy. Front Oncol. 2020;10:1080. doi:10.3389/fonc.2020.01080
   PubMed Web of Science ®Google Scholar
• Su T, Huang M, Liao J, et al. Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism. Hepatology. 2021;74(3):1339–1356. doi:10.1002/hep.31766
   PubMed Web of Science ®Google Scholar
• Zhang BN, Liu Y, Yang Q, et al. rad21 Is Involved in Corneal Stroma Development by Regulating Neural Crest Migration. Int J Mol Sci. 2020;21(20). doi:10.3390/ijms21207807
   Web of Science ®Google Scholar
• Mintzas K, Heuser M. Emerging strategies to target the dysfunctional cohesin complex in cancer. Expert Opin Ther Targets. 2019;23(6):525–537. doi:10.1080/14728222.2019.1609943
   PubMed Web of Science ®Google Scholar
• Xu H, Yan M, Patra J, et al. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Res. 2011;13(1):R9. doi:10.1186/bcr2814
   PubMed Web of Science ®Google Scholar
• Yamamoto G, Irie T, Aida T, Nagoshi Y, Tsuchiya R, Tachikawa T. Correlation of invasion and metastasis of cancer cells, and expression of the RAD21 gene in oral squamous cell carcinoma. Virchows Arch. 2006;448(4):435–441. doi:10.1007/s00428-005-0132-y
   PubMed Web of Science ®Google Scholar
• Deb S, Xu H, Tuynman J, et al. RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. Br J Cancer. 2014;110(6):1606–1613. doi:10.1038/bjc.2014.31
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao H, Yu J, et al. MiR-320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. Cancer Sci. 2021;112(2):575–588. doi:10.1111/cas.14751
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Mollica V, et al. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596. doi:10.1016/j.critrevonc.2022.103596
   PubMed Web of Science ®Google Scholar
• Mollica V, Rizzo A, Marchetti A, et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med. 2023. doi:10.1007/s10238-023-01159-1
   Web of Science ®Google Scholar
• Liu CZ, Guo WP, Peng JB, et al. Clinical significance of CCNE2 protein and mRNA expression in thyroid cancer tissues. Adv Med Sci. 2020;65(2):442–456. doi:10.1016/j.advms.2020.09.001
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Yang Y, Ren P, Liu X, et al. PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2022;41(1):101. doi:10.1186/s13046-022-02302-8
   PubMed Web of Science ®Google Scholar
• Hu C, Xin Z, Sun X, et al. Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress. J Exp Clin Cancer Res. 2023;42(1):108. doi:10.1186/s13046-023-02656-7
   PubMed Web of Science ®Google Scholar
• Lambert SA, Jolma A, Campitelli LF, et al. The Human Transcription Factors. Cell. 2018;172(4):650–665. doi:10.1016/j.cell.2018.01.029
   PubMed Web of Science ®Google Scholar
• Alerasool N, Leng H, Lin ZY, Gingras AC, Taipale M. Identification and functional characterization of transcriptional activators in human cells. Mol Cell. 2022;82(3):677–695 e7. doi:10.1016/j.molcel.2021.12.008
   PubMed Web of Science ®Google Scholar
• Haberle V, Arnold CD, Pagani M, Rath M, Schernhuber K, Stark A. Transcriptional cofactors display specificity for distinct types of core promoters. Nature. 2019;570(7759):122–126. doi:10.1038/s41586-019-1210-7
   PubMed Web of Science ®Google Scholar
• Song J, Xie C, Jiang L, et al. Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/beta-catenin pathway in hepatocellular carcinoma. Theranostics. 2018;8(13):3571–3583. doi:10.7150/thno.25194
   PubMed Web of Science ®Google Scholar
• An T, Dong T, Zhou H, et al. The transcription factor Kruppel-like factor 5 promotes cell growth and metastasis via activating PI3K/AKT/Snail signaling in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019;508(1):159–168. doi:10.1016/j.bbrc.2018.11.084
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang K, Deng Q, Li W, Zhang X, Liu X. Identification of Key Hydroxymethylated Genes and Transcription Factors Associated with Alpha-Fetoprotein-Negative Hepatocellular Carcinoma. DNA Cell Biol. 2019;38(11):1346–1356. doi:10.1089/dna.2019.4689
   PubMed Web of Science ®Google Scholar
• Ji X, Chen X, Zhang B, et al. T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1. Oncogene. 2022;41(15):2225–2238. doi:10.1038/s41388-022-02249-2
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhang N, Pati D. Cohesin subunit RAD21: from biology to disease. Gene. 2020;758:144966. doi:10.1016/j.gene.2020.144966
   PubMed Web of Science ®Google Scholar
• Cui R, Chen P, Wang Y, et al. Cohesin RAD21 Gene Promoter Methylation Correlated with Better Prognosis in Breast Cancer Patients. Cytogenet Genome Res. 2022;162(3):109–118. doi:10.1159/000524735
   PubMed Web of Science ®Google Scholar
• Atienza JM, Roth RB, Rosette C, et al. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol Cancer Ther. 2005;4(3):361–368. doi:10.1158/1535-7163.MCT-04-0241
   PubMed Web of Science ®Google Scholar
• Deng P, Wang Z, Chen J, et al. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022;132(22). doi:10.1172/JCI159628
   Web of Science ®Google Scholar
• Sakabe T, Wakahara M, Shiota G, Umekita Y. Role of cytoplasmic localization of maspin in promoting cell invasion in breast cancer with aggressive phenotype. Sci Rep. 2021;11(1):11321. doi:10.1038/s41598-021-90887-z
   PubMed Web of Science ®Google Scholar
• Harold CM, Buhagiar AF, Cheng Y, Baserga SJ. Ribosomal RNA Transcription Regulation in Breast Cancer. Genes. 2021;12(4). doi:10.3390/genes12040502
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang Y, Li D, Zhang H, Guo Z, Yang X. Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity. Cancer Cell Int. 2020;20:487. doi:10.1186/s12935-020-01583-3
   PubMed Web of Science ®Google Scholar
• Morse MA, Sun W, Kim R, et al. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019;25(3):912–920. doi:10.1158/1078-0432.CCR-18-1254
   PubMed Web of Science ®Google Scholar
• Shang N, Wang H, Bank T, et al. Focal Adhesion Kinase and beta-Catenin Cooperate to Induce Hepatocellular Carcinoma. Hepatology. 2019;70(5):1631–1645. doi:10.1002/hep.30707
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ye W, Wang YD, Chen WD. HGF/c-Met: a Key Promoter in Liver Regeneration. Front Pharmacol. 2022;13:808855. doi:10.3389/fphar.2022.808855
   PubMed Web of Science ®Google Scholar
• Han T, Zheng H, Zhang J, et al. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis. Cell Death Dis. 2022;13(3):200. doi:10.1038/s41419-022-04652-9
   PubMed Web of Science ®Google Scholar
• Yu J, Xia X, Dong Y, et al. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling. Theranostics. 2021;11(5):2123–2136. doi:10.7150/thno.49368
   PubMed Web of Science ®Google Scholar
• Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol. 2022;221:1428–1438. doi:10.1016/j.ijbiomac.2022.09.129
   PubMed Web of Science ®Google Scholar